To include your compound in the COVID-19 Resource Center, submit it here.

New efficacy data for Pfizer's 4-1BB, OX40 programs

Abstracts published ahead of next month's American Society of Clinical Oncology (ASCO) meeting included data for a pair of next-generation immuno-oncology programs from Pfizer Inc. (NYSE:PFE).

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE